Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Evaxion Biotech A/S
EVAX | US
4.14
USD0
0%
EVAX | US
About Evaxion Biotech A/S
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
15/04/2026
Close
4.14
Open
4.13
High
4.14
Low
3.97
Evaxion Biotech A/S a clinical-stage biotech company engages in developing artificial intelligence-powered immunotherapies for cancers bacterial diseases and viral infections. The company develops EVX-01 a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02 a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03 a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1 EVX-B2 and EVX-V1 which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm Denmark.
View LessEVAX | US
Risk
58.2
Sharpe
1.66
Luna's Score
48/100
Recommendation
Hold
Luna says (EVAX | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Strong Sharpe Ratio (> 1.2)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
53.5%1 month
58.2%3 months
86.1%6 months
118.2%Returns
Fundamental Ratios
PE
-
Fwd. PE
3.57
Price to book
12.06
Debt to equity
8.37
Debt to assets
0.69
Ent. to EBITDA
-0.59
Ent. to rev.
63.35
PEG
-
Other Fundamentals
EBITDA
-18.80M
MarketCap
23.09M
MarketCap(USD)
23.09M
Div. yield
-
Op. margin
-2.97K
Erngs. growth
-
Rev. growth
-
Ret. on equity
-802.80
Short ratio
0.90
Short perc.
2.14
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
1.18
Range1M
1.20
Range3M
2.31
Volumes: Market Activity
Rel. volume
0.96
Price X volume
92.24K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.59 | - | Cheaper |
| Ent. to Revenue | 63.35 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 12.06 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 86.08 | - | Par |
| Debt to Equity | 8.37 | -1.23 | Expensive |
| Debt to Assets | 0.69 | 0.25 | Expensive |
| Market Cap | 23.09M | - | Emerging |
